Otsuka Pharmaceutical Europe Ltd
🇧🇪Belgium
Clinical Trials
8
Active:0
Completed:6
Trial Phases
1 Phases
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 4
1 (100.0%)Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 119
- Registration Number
- NCT03130478
- Locations
- 🇪🇸
Hospital Universitario de Álava, Alava, Spain
🇪🇸Hospital Fundación Alcorcón, Alcorcón, Spain
🇪🇸Numància Salut Mental (Parc Sanitari St Joan de Deu), Barcelona, Spain
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 636
- Registration Number
- NCT03130465
- Locations
- 🇫🇷
H. Paul-Guiraud Clamart, Clamart, France
🇫🇷CH Jonzac, Jonzac, France
🇫🇷Centre Psychotherapique Nancy, Laxou, France
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 262
- Registration Number
- NCT03005769
- Locations
- 🇮🇹
Centro Salute Mentale, Ancona, Italy
🇮🇹SPDC ASST Spedali Civili, Brescia, Italy
🇮🇹Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 407
- Registration Number
- NCT02848521
- Locations
- 🇦🇹
AKH Wien, Vienna, Austria
🇦🇹LKH Villach, Villach, Austria
🇧🇪UCL Brussels, Brussels, Belgium
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
Completed
- Conditions
- CancerHyponatremiaSyndrome of Inappropriate ADH (SIADH) Secretion
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Otsuka Pharmaceutical Europe Ltd
- Target Recruit Count
- 69
- Registration Number
- NCT02573077
- Prev
- 1
- 2
- Next
News
No news found